Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension | Zendy

David V. Glidden | Zendy; K. Rivet Amico | Zendy; Albert Liu | Zendy; Sybil Hosek | Zendy; Peter L. Anderson | Zendy; Susan Buchbinder | Zendy; Vanessa McMahan | Zendy; Kenneth H. Mayer | Zendy; Burns David | Zendy; Mauro Schechter | Zendy; Beatriz Grinsztejn | Zendy; Juan V. Guanira | Zendy; Robert M. Grant | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension

Author(s) -

David V. Glidden,

K. Rivet Amico,

Albert Liu,

Sybil Hosek,

Peter L. Anderson,

Susan Buchbinder,

Vanessa McMahan,

Kenneth H. Mayer,

Burns David,

Mauro Schechter,

Beatriz Grinsztejn,

Juan V. Guanira,

Robert M. Grant

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw022

Subject(s) - medicine , emtricitabine , confidence interval , open label , odds ratio , cohort , pre exposure prophylaxis , cohort study , clinical trial , adverse effect , prospective cohort study , pediatrics , human immunodeficiency virus (hiv) , viral load , men who have sex with men , antiretroviral therapy , immunology , syphilis

Blinded clinical trials have reported a modest and transient "start-up syndrome" with initiation of tenofovir-based pre-exposure prophylaxis (PrEP). We evaluate this phenomenon and its effect on adherence in an open-label PrEP study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research